Seaport Therapeutics

SPTX

Market cap $1.03B

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™.

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers.

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to participate in two upcoming investor conferences.